Targeted radiation zaps bone tumors in new trial

NCT ID NCT02880319

Ongoing Disease control Sponsor: Dana-Farber Cancer Institute Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This phase 2 trial tests a high-precision radiation therapy called SBRT for people whose cancer has spread to the spine or other bones. The goal is to see if SBRT can control tumor growth at the treated spots for at least 6 months. About 150 adults with solid tumors (not blood cancers) and up to 3 affected vertebrae are being enrolled.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Stereotactic body radiation therapy (SBRT)
What this could lead to: If successful, this could provide a non-surgical option to control cancer that has spread to bones, potentially improving local tumor control and quality of life.
What could go wrong: This is a mid-stage trial with only 150 participants, so results may not apply to all patients. Radiation can cause side effects like pain or fracture, and the treatment may not prevent cancer from spreading elsewhere.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BONE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

bone cancer metastatic carcinoma in the bone

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BONE CANCER

Contacts and locations

Locations

Dana Farber Cancer Institute

Boston, Massachusetts, 02115, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.